CSTF3

Across TCGA pan-cancer cohorts, CSTF3 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated CSTF3 data layer compared with 26 for mass-spec protein and 11 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher CSTF3 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated CSTF3 expression acts as an unfavorable survival marker, although some lineages such as COAD and LUAD show a favorable association.

PDAC, HNSC, and COAD are the cancer types where CSTF3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Tertile	All	0.425	0.684	<.001	95	view →
HNSC	OS	Quartile	All	0.776	0.922	.014	28	view →
COAD	DFS	Quartile	All	1.000	0.897	.043	12	view →
LUAD	OS	Quartile	All	1.000	0.807	.018	6	view →
LSCC	DFS	Tertile	II,III,IV	0.848	0.507	.019	6	view →
CCRCC	DFS	Median	All	0.725	0.892	.028	3	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

CSTF3–PDAC (OS)

Open the PDAC breakdown →